AGMT Austrian Lymphoma Registry - Trial NCT06294652
Access comprehensive clinical trial information for NCT06294652 through Pure Global AI's free database. This phase not specified trial is sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 4000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Arbeitsgemeinschaft medikamentoese Tumortherapie
Timeline & Enrollment
N/A
Feb 27, 2024
Dec 31, 2033
Primary Outcome
General Characteristics,Genetic Profiling,Proportion of lymphoma patients in Austria that require treatment,Proportion of lymphoma patients in Austria under active surveillance,Number of patients with concomitant diseases,Number of treatment and outcome of treatment,Patient Outcome,Toxicities
Summary
Lymphomas are a group of cancers that originate in the lymphatic system, a key component of
 the immune system. They can be broadly categorized into two main types: Hodgkin lymphoma (HL)
 and non-Hodgkin lymphoma (NHL).
 
 There are different subtypes of HL, including classical Hodgkin lymphoma (cHL) and nodular
 lymphocyte-predominant Hodgkin lymphoma (NLPHL). The subtypes of cHL include nodular
 sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted.
 
 Non-Hodgkin lymphomas are more diverse and comprise a wide range of subtypes, each with
 distinct genetic, molecular, and clinical features. Common subtypes of NHL include Diffuse
 large B-cell lymphoma (DLBCL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), Chronic
 lymphocytic leukemia (CLL), myeloma, and other rarer subgroups.
 
 Many of these diseases typically present with lymph node enlargement, bone marrow
 infiltration, general and lymphoma subtype specific symptoms and laboratory abnormalities.
 
 Novel agents have improved the prognosis of high-risk lymphoma patients in the front-line and
 relapsed setting and more accurate prognostic tools enable less intensive treatment for
 low-risk patients, while maintaining their good prognosis.
 
 Lymphoma disease have not been systematically assessed in Austria to date. This medical
 registry of the AGMT is thus the first Austrian-wide standardized documentation of
 epidemiology, clinical course and molecular and other biologic data of this disease. As
 lymphomas are a very heterogeneous group, not all subtypes will always be documented
 simultaneously in this registry. Which lymphoma subtype is to be documented can change over
 time, depending on which clinical question is currently in focus.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06294652
Non-Device Trial